Selected publications 

  • Khaleafi R, Zeleznjak J, Cordela S, Drucker S, Roviš T, Jonjic S, Bar-On Y. Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality. Front. Immunol. 2023 (14) 2023

 

  • Khateeb, D., Gabrieli, T., Sofer, B., Hattar, A., Cordela, S., Chaouat, A., Spivak, I., Lejbkowicz, I., Almog, R., Mandelboim, M. and Bar-On, Y., 2022. SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. PLoS pathogens18(1), p.e1010242.

 

  • Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, Melamed D, Kessel A, Bar-On Y. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology. 2021 Nov 25

 

  • Bar-On Y*, Gruell H*, Schoofs H, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS, Fätkenheuer G, Caskey M, Klein F, Michel C. Nussenzweig. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic Individuals. Nature medicine24 (11): 1701-1707 (2018).
  • Featured in Nature news and views: Haigwood LN, Antibodies pose a double threat to HIV. Nature(2018): 468

 

  • Horwitz JA*, Bar-On Y*, Lu CL*, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC. Non-neutralizing antibodies alter the course of HIV-1 infection in Vivo. Cell.(4): 637-648 (2017).

 

  • Bar-On Y*, Charpak-Amikam Y*, Glasner A, Isaacson B, Duev-Cohen A, Tsukerman P, Varvak A, Mandelboim M, Mandelboim O. NKp46 recognizes the sigma1 protein of reovirus: Implications for reovirus-based cancer therapy. Journal of virology. (19): e01045-17 (2017).

 

  • Bar-On Y, Seidel E, Tsukerman P, Mandelboim M, Mandelboim O. Influenza virus uses its neuraminidase protein to evade the recognition of the NKp46 and NKp44 activating NK cell receptors. TheJournal of infectious diseases. 210 (3): 410-418 (2014).

 

  • Bar-On Y, Glasner A, Meningher T, Achdout H, Gur C, Lankry D, Vitenshtein A, Meyers AF, Mandelboim M., Mandelboim, O. Neuraminidase-mediated, NKp46-dependent immune-evasion mechanism of influenza viruses. Cell reports. 3(4): 1044-1050 (2013).

          Press here for the full list of publications